Team:UC Davis E/Bioindustrial Enzyme

From 2012e.igem.org

(Difference between revisions)
 
(2 intermediate revisions not shown)
Line 127: Line 127:
#menubar.right-menu { width:300px; display:block; float:left; margin-top:-80px; border: none;}
#menubar.right-menu { width:300px; display:block; float:left; margin-top:-80px; border: none;}
.right-menu ul { border: none; width: 300px;}
.right-menu ul { border: none; width: 300px;}
-
#footer-box { background-color: #216085; border: none; width: 100%; height: 100%; margin: -10px auto 0 auto; padding: 20px 0;}
+
#footer-box { background-color: rgba(191, 191, 191, 0.5); border: none; width: 850px; height: 30px; margin: -10px auto 0 auto; padding: 20px 0;}
.visualClear { display: none; }
.visualClear { display: none; }
#footer { border: none; width: 850px; margin: 0 auto; padding: 0;}
#footer { border: none; width: 850px; margin: 0 auto; padding: 0;}
Line 139: Line 139:
h3#siteSub { display: none;}
h3#siteSub { display: none;}
#contentSub {display: none;}
#contentSub {display: none;}
-
p:first-child { display: none;}
+
p:first-child { display: block;}
h1{border:none; width: 100%; clear: both;}
h1{border:none; width: 100%; clear: both;}
<!-- end of slides style -->
<!-- end of slides style -->
Line 338: Line 338:
padding: 15px 15px 15px 15px;
padding: 15px 15px 15px 15px;
font: sans-serif;
font: sans-serif;
-
font-size: 16px;
+
font-size: 17px;
line-height:1.5em;
line-height:1.5em;
color:black;
color:black;
Line 352: Line 352:
font-weight:bold;
font-weight:bold;
}
}
 +
 +
#myleftbox .smallboxsite
 +
{
 +
width:820px;
 +
float:left;
 +
background-color:rgba(191,191,191,0.6 );
 +
margin-top: 17px;
 +
border-radius: 4px;
 +
padding: 15px 15px 15px 15px;
 +
font: sans-serif;
 +
font-size: 13px;
 +
line-height:1.5em;
 +
color:black;
 +
 +
}
 +
#myleftbox .threeboxes
#myleftbox .threeboxes
Line 588: Line 604:
 +
#catlinks {
 +
background-color:transparent;
 +
border:1px solid transparent;
 +
}
 +
#footpage {
 +
background-color:transparent;
 +
}
 +
#footer-box {
 +
background-color:rgba(191,191,191,0.5);
 +
}
#footer-box-1 {
#footer-box-1 {
          
          
Line 595: Line 621:
         margin: 0 auto;
         margin: 0 auto;
         border: 1px solid #444444;
         border: 1px solid #444444;
 +
}
}
table {
table {
Line 707: Line 734:
</td>
</td>
-
<td style="vertical-align:top"><img src="https://static.igem.org/mediawiki/2012e/f/fd/UCD_Buttons.jpg" width="400" height="300"></td>
+
<td style="vertical-align:top"><img src="https://static.igem.org/mediawiki/2012e/7/7e/UCD_E4.jpg"></td>
</tr>
</tr>
</table>
</table>
Line 715: Line 742:
</div>
</div>
 +
<!-- site map starts here -->
 +
<div id="myleftbox"  class="smallboxsite" style=" margin-top: 6px; padding-top: 15px; padding-left: 350px; width: 485px;">
 +
<ul style="font-size:10px;list-style-image:none;list-style-type:none;float:left;display:inline;color:#000000;"  >
 +
 +
<li style="float:left ;margin:0 10px;"><a href="https://2012e.igem.org/Team:UC_Davis_E/Terms_of_Use"> <p>Legal</p></a></li>
 +
<li style="float:left ;margin:0 10px;"><a href="https://2012e.igem.org/Team:UC_Davis_E/Site_Map"> <p>Site Map</p></a></li>
 +
 +
</ul>
</div>
</div>
-
</div>
+
<!-- site map ends here -->
<!--  </div> -->
<!--  </div> -->

Latest revision as of 03:21, 28 October 2012

Team:UC Davis - 2012.igem.org




Bioindustrial Enzyme

We identify the need for renewable alternatives through both our own research and through insights gleaned from our partners and customers in the market place. We investigate the key molecular properties that are essential to a current product’s performance and then analyze the chemical structures that drive those characteristics. Understanding of these chemical structures allows us to identify target molecules or simple derivatives of molecules that may be produced by our engineered biological systems.
We then apply our proprietary technology to the pursuit of this target molecule. The key components of our industrial synthetic biology platform are strain engineering, process development, and scale-up.

Strain Engineering: The primary biological pathway within the microbe that we currently use to produce our target molecules is the secretion of a novel catalyst. The overproduction and purification of the catalyst will serve as enough quantity to effectively initiate degradation. Our platform utilizes proprietary high-throughput processes to create and test evolving strains in order to choose those specific strains that are most efficient and scalable.

Process Development and Scale-up: The basis of our production is a well-established fermentation process that uses our genetically-engineered microorganism strains to convert the plastic source into target molecules such as terephthalic acid. We will employ a multi-stage scale-up approach to progress from laboratory scale to commercial production scale. Once scaled up, AmberCycle scientists will maintain a constant feedback loop with or fermentation process and our laboratory, where strains are continuously created and modified, in hopes to expose those strains to conditions that simulate a commercial production environment. This allows us to focus our microbe development resources on those strains that demonstrate the highest potential to scale effectively.